Cantor Fitzgerald Predicts Arcellx FY2025 Earnings

Key Points

• Cantor Fitzgerald projects Arcellx's FY2025 earnings per share at ($2.98), significantly lower than the current consensus estimate of ($1.58) per share.
• The company's stock is receiving positive attention from numerous analysts, with a consensus rating of "Buy" and an average target price of $114.31.
• Insider transactions show that Director Kavita Patel sold shares for a total of $101,040, while hedge funds collectively own 96.03% of Arcellx's stock.

Arcellx, Inc. (NASDAQ:ACLX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Arcellx in a research report issued on Monday, August 4th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($2.98) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Arcellx's current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx's FY2026 earnings at ($2.65) EPS.

Other analysts also recently issued research reports about the stock. Scotiabank boosted their price objective on shares of Arcellx from $93.00 to $133.00 and gave the stock a "sector outperform" rating in a research report on Thursday, July 31st. Citigroup initiated coverage on shares of Arcellx in a research note on Tuesday, June 17th. They issued a "buy" rating and a $110.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $115.00 target price on shares of Arcellx in a research report on Monday, June 16th. Thirteen research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $114.31.

Arcellx Trading Down 0.9%

ACLX stock traded down $0.65 during trading on Wednesday, hitting $70.50. 867,672 shares of the company's stock were exchanged, compared to its average volume of 446,817. The business has a 50-day moving average price of $67.52 and a two-hundred day moving average price of $65.21. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -20.61 and a beta of 0.28. Arcellx has a 52-week low of $47.86 and a 52-week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.09. Arcellx had a negative return on equity of 41.63% and a negative net margin of 329.93%. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $16.76 million.

Insider Buying and Selling

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $67.36, for a total transaction of $101,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arcellx

Several hedge funds have recently modified their holdings of ACLX. American Century Companies Inc. acquired a new position in Arcellx in the 4th quarter valued at $2,258,000. Sei Investments Co. boosted its holdings in shares of Arcellx by 99.3% in the fourth quarter. Sei Investments Co. now owns 9,688 shares of the company's stock valued at $743,000 after acquiring an additional 4,827 shares in the last quarter. Norges Bank acquired a new position in shares of Arcellx during the fourth quarter worth about $2,090,000. Pictet Asset Management Holding SA increased its stake in shares of Arcellx by 40.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 4,945 shares of the company's stock worth $379,000 after acquiring an additional 1,426 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Arcellx by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 979,026 shares of the company's stock worth $75,098,000 after purchasing an additional 4,059 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).